1
|
Álvarez K, Rojas M. Nanoparticles targeting monocytes and macrophages as diagnostic and therapeutic tools for autoimmune diseases. Heliyon 2023; 9:e19861. [PMID: 37810138 PMCID: PMC10559248 DOI: 10.1016/j.heliyon.2023.e19861] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 08/16/2023] [Accepted: 09/04/2023] [Indexed: 10/10/2023] Open
Abstract
Autoimmune diseases are chronic conditions that result from an inadequate immune response to self-antigens and affect many people worldwide. Their signs, symptoms, and clinical severity change throughout the course of the disease, therefore the diagnosis and treatment of autoimmune diseases are major challenges. Current diagnostic tools are often invasive and tend to identify the issue at advanced stages. Moreover, the available treatments for autoimmune diseases do not typically lead to complete remission and are associated with numerous side effects upon long-term usage. A promising strategy is the use of nanoparticles that can be used as contrast agents in diagnostic imaging techniques to detect specific cells present at the inflammatory infiltrates in tissues that are not easily accessible by biopsy. In addition, NPs can be designed to deliver drugs to a cell population or tissue. Considering the significant role played by monocytes in the development of chronic inflammatory conditions and their emergence as a target for extracorporeal monitoring and precise interventions, this review focuses on recent advancements in nanoparticle-based strategies for diagnosing and treating autoimmune diseases, with a particular emphasis on targeting monocyte populations.
Collapse
Affiliation(s)
- Karen Álvarez
- Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria (SIU), Universidad de Antioquia (UDEA), Colombia
| | - Mauricio Rojas
- Grupo de Inmunología Celular e Inmunogenética, Sede de Investigación Universitaria (SIU), Universidad de Antioquia (UDEA), Colombia
- Unidad de Citometría de Flujo, Sede de Investigación Universitaria (SIU), Universidad de Antioquia (UDEA), Colombia
| |
Collapse
|
2
|
Mannering SI, Rubin AF, Wang R, Bhattacharjee P. Identifying New Hybrid Insulin Peptides (HIPs) in Type 1 Diabetes. Front Immunol 2021; 12:667870. [PMID: 33995402 PMCID: PMC8120023 DOI: 10.3389/fimmu.2021.667870] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2021] [Accepted: 04/15/2021] [Indexed: 11/13/2022] Open
Abstract
In 2016 Delong et al. discovered a new type of neoepitope formed by the fusion of two unrelated peptide fragments. Remarkably these neoepitopes, called hybrid insulin peptides, or HIPs, are recognized by pathogenic CD4+ T cells in the NOD mouse and human pancreatic islet-infiltrating T cells in people with type 1 diabetes. Current data implicates CD4+ T-cell responses to HIPs in the immune pathogenesis of human T1D. Because of their role in the immune pathogenesis of human T1D it is important to identify new HIPs that are recognized by CD4+ T cells in people at risk of, or with, T1D. A detailed knowledge of T1D-associated HIPs will allow HIPs to be used in assays to monitor changes in T cell mediated beta-cell autoimmunity. They will also provide new targets for antigen-specific therapies for T1D. However, because HIPs are formed by the fusion of two unrelated peptides there are an enormous number of potential HIPs which makes it technically challenging to identify them. Here we review the discovery of HIPs, how they form and discuss approaches to identifying new HIPs relevant to the immune pathogenesis of human type 1 diabetes.
Collapse
Affiliation(s)
- Stuart I Mannering
- Immunology and Diabetes Unit, St. Vincent's Institute of Medical Research, Melbourne, VIC, Australia.,Department of Medicine, University of Melbourne, St. Vincent's Hospital, Melbourne, VIC, Australia
| | - Alan F Rubin
- Bioinformatics Division, Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.,Department of Medical Biology, University of Melbourne, Melbourne, VIC, Australia
| | - Ruike Wang
- Immunology and Diabetes Unit, St. Vincent's Institute of Medical Research, Melbourne, VIC, Australia
| | - Pushpak Bhattacharjee
- Immunology and Diabetes Unit, St. Vincent's Institute of Medical Research, Melbourne, VIC, Australia
| |
Collapse
|
3
|
Sinha S, Renavikar PS, Crawford MP, Steward-Tharp SM, Brate A, Tsalikian E, Tansey M, Shivapour ET, Cho T, Kamholz J, Karandikar NJ. Altered expression of SIRPγ on the T-cells of relapsing remitting multiple sclerosis and type 1 diabetes patients could potentiate effector responses from T-cells. PLoS One 2020; 15:e0238070. [PMID: 32853219 PMCID: PMC7451561 DOI: 10.1371/journal.pone.0238070] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2020] [Accepted: 08/08/2020] [Indexed: 11/19/2022] Open
Abstract
Factors regulating self-antigen directed immune-responses in autoimmunity are poorly understood. Signal regulatory protein gamma (SIRPγ) is a human T-cell specific protein with genetic variants associated with type 1 diabetes (T1D). SIRPγ's function in the immune system remains unclear. We show that T1D and relapsing remitting multiple sclerosis (RRMS) subjects have significantly greater frequency of rs2281808 T genetic variant, that correlates with reduced SIRPγ-expression in T-cells. Importantly, reduced SIRPγ-expression in RRMS and T1D subjects was not restricted to T variant, suggesting SIRPγ-expression is also regulated by disease specific factors in autoimmunity. Interestingly, increased frequencies of SIRPγlow T-cells in RRMS and T1D positively correlated with proinflammatory molecules from T-cells. Finally, we show that SIRPγlow T-cells have enhanced pathogenecity in vivo in a GVHD model. These findings suggest that decreased-SIRPγ expression, either determined by genetic variants or through peripherally acquired processes, may have a mechanistic link to autoimmunity through induction of hyperactive T-cells.
Collapse
Affiliation(s)
- Sushmita Sinha
- Department of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America
- * E-mail:
| | - Pranav S. Renavikar
- Department of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Michael P. Crawford
- Department of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Scott M. Steward-Tharp
- Department of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America
- Department of Oral Pathology, Radiology and Medicine, College of Dentistry, University of Iowa, Iowa City, Iowa, United States of America
| | - Ashley Brate
- Department of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Eva Tsalikian
- Department of Pediatrics, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Michael Tansey
- Department of Pediatrics, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Ezzatollah T. Shivapour
- Department of Neurology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Tracey Cho
- Department of Neurology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - John Kamholz
- Department of Neurology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| | - Nitin J. Karandikar
- Department of Pathology, University of Iowa Health Care, Iowa City, Iowa, United States of America
| |
Collapse
|
4
|
Murfitt SA, Zaccone P, Wang X, Acharjee A, Sawyer Y, Koulman A, Roberts LD, Cooke A, Griffin JL. Metabolomics and Lipidomics Study of Mouse Models of Type 1 Diabetes Highlights Divergent Metabolism in Purine and Tryptophan Metabolism Prior to Disease Onset. J Proteome Res 2018; 17:946-960. [PMID: 28994599 DOI: 10.1021/acs.jproteome.7b00489] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
With the increase in incidence of type 1 diabetes (T1DM), there is an urgent need to understand the early molecular and metabolic alterations that accompany the autoimmune disease. This is not least because in murine models early intervention can prevent the development of disease. We have applied a liquid chromatography (LC-) and gas chromatography (GC-) mass spectrometry (MS) metabolomics and lipidomics analysis of blood plasma and pancreas tissue to follow the progression of disease in three models related to autoimmune diabetes: the nonobese diabetic (NOD) mouse, susceptible to the development of autoimmune diabetes, and the NOD-E (transgenic NOD mice that express the I-E heterodimer of the major histocompatibility complex II) and NOD-severe combined immunodeficiency (SCID) mouse strains, two models protected from the development of diabetes. All three analyses highlighted the metabolic differences between the NOD-SCID mouse and the other two strains, regardless of diabetic status indicating that NOD-SCID mice are poor controls for metabolic changes in NOD mice. By comparing NOD and NOD-E mice, we show the development of T1DM in NOD mice is associated with changes in lipid, purine, and tryptophan metabolism, including an increase in kynurenic acid and a decrease in lysophospholipids, metabolites previously associated with inflammation.
Collapse
Affiliation(s)
- Steven A Murfitt
- Department of Biochemistry, University of Cambridge , The Sanger Building, 80 Tennis Court Road, Cambridge CB2 1GA, U.K
| | - Paola Zaccone
- Department of Pathology, University of Cambridge , Tennis Court Road, Cambridge CB2 1QP, U.K
| | - Xinzhu Wang
- Department of Biochemistry, University of Cambridge , The Sanger Building, 80 Tennis Court Road, Cambridge CB2 1GA, U.K
| | - Animesh Acharjee
- Medical Research Council Human Nutrition Research, The Elsie Widdowson Laboratory , 120 Fulbourn Road, Cambridge CB1 9NL, U.K
| | - Yvonne Sawyer
- Department of Pathology, University of Cambridge , Tennis Court Road, Cambridge CB2 1QP, U.K
| | - Albert Koulman
- Medical Research Council Human Nutrition Research, The Elsie Widdowson Laboratory , 120 Fulbourn Road, Cambridge CB1 9NL, U.K
| | - Lee D Roberts
- Medical Research Council Human Nutrition Research, The Elsie Widdowson Laboratory , 120 Fulbourn Road, Cambridge CB1 9NL, U.K
| | - Anne Cooke
- Department of Pathology, University of Cambridge , Tennis Court Road, Cambridge CB2 1QP, U.K
| | - Julian Leether Griffin
- Department of Biochemistry, University of Cambridge , The Sanger Building, 80 Tennis Court Road, Cambridge CB2 1GA, U.K.,Medical Research Council Human Nutrition Research, The Elsie Widdowson Laboratory , 120 Fulbourn Road, Cambridge CB1 9NL, U.K
| |
Collapse
|